Skip to content

RTO Details

On 29 November 2023, Promore Pharma AB (reg. no. 556639-6809) announced the proposed acquisition of all the shares in PMD Device Solutions AB (reg. no. 559305-4173) by making a payment to the shareholders of PMD Device Solutions AB in the form of newly issued shares in Promore Pharma AB. The Transaction constitutes a so-called reverse acquisition.

PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities. The board of PMD believes that a listing on First North will provide a quality stamp that contributes to confidence in discussions with potential customers and partners and an increased interest in PMD from the public, investors and other stakeholders. The Transaction will also enhance the conditions for creating shareholder value and gives PMD access to the capital market. The access to the stock market will also facilitate the implementation of the PMD’s growth plans and ambition to expand the business into new markets globally. 

As part of the Transaction, Promore Pharma AB will undergo a name change to PMD Device Solutions AB and will continue to operate PMD’s business.



Myles Murray, CEO

If you have more general investor related enquires, please contact us via: